Fosun leads the investment in "Fruit Health", and the home health management track becomes a "fragrant feast" in the eyes of capital.

Per reporter: Yao Yanan Tang Ruyu Per reporter: Xiao Ruidong

Today, Fruit Health announced the completion of a MULTI-A round of financing of tens of millions of yuan, led by Fosun Health and Challenger Venture Capital, and followed by Gimpo Investment. It is reported that Fruit Health is a service platform for family chronic disease management based on Internet of Things, big data and AI technology.

The Healthy China Initiative (2019-2030) points out that chronic noncommunicable diseases (hereinafter referred to as chronic diseases) have become the main cause of death and disease burden of residents. How to effectively prevent, manage and manage chronic diseases has become an important issue related to people's livelihood and health, and more scientific and technological means are urgently needed. Every reporter noticed that in recent years, smart home health management has gradually become a track that has attracted much attention from capital, attracting Internet giants and first-line venture capital institutions to compete for layout.

In this regard, Zhu Shuyan, vice president of Gimpo Investment, told reporters that home intelligent medical and health management is a track driven by the supply side, "whether it is the demand for family health or chronic disease management, there is an objective existence, but to a large extent, the entire market is driven by supply, and we will pay attention to the transformation of advanced technology in the stock field and the mining of the incremental market."

Household intelligent medical products are booming, and investors are most concerned about research and development capabilities

The reporter noted that based on the family demand scenario, "Fruit Health" has launched medical-grade products such as intelligent urine testers and 24-hour holters, as well as consumer health products such as intelligent posture elves and intelligent fat burning elves. He Xin, co-founder of the company, believes that smart home medical products are still in their infancy, not only the product hardware needs to be redesigned, but also the processing, analysis and APP application technology requirements for health data are high.

Gimpo Investment is the financier of this round of "Fruit Health", and Zhu Shuyan, vice president of the company's investment, has long been concerned about the smart home medical track. She told reporters that product development ability is the primary factor of concern in the investment process, "whether there is a professional and scientific medical theory behind the product, whether the entrepreneur can uphold humanistic care, along the intelligent, miniaturized, household ideas to carry out product development is what we value most."

In her view, there was a service gap between traditional enterprises and users, and traditional enterprises could only provide monitoring products, and if abnormal monitoring data was found, users needed to seek help from professional medical institutions. However, innovative enterprises such as "Fruit Health" can build a big data middle platform through technologies such as the Internet of Things and artificial intelligence, which can not only help users read medical data, but also connect more medical resources in the follow-up, provide users with medication reminders, living habits and other aspects of intervention guidance, and achieve more convenient health management.

The reporter noted that since last year, smart medical products for family scenarios have repeatedly won financing. In December 2021, "Deep Napusi" announced the completion of tens of millions of dollars in financing, led by Xiaomi Group, and followed by capital and source code capital. In the interview, Shennapusi told reporters that its wearable smart products in research focus on common chronic diseases such as "three highs" and Alzheimer's disease, and the company hopes to introduce top consumer electronics technology ideas to do medical-grade products. "Kailian Medical" completed two rounds of financing in 2021, and the investor lineup is quite luxurious, including Qianhai Fund of Funds, Oriental Fuhai, Legend Capital, etc., which mainly focuses on the field of diabetes and launches intelligent hardware products for drug infusion. Zhenluo Sciences, which also announced its $100 million financing last year, has developed smart devices for Parkinson's disease, providing integrated solutions including diagnosis, assessment, treatment, rehabilitation and personalized management.

Supply-driven demand "stock + incremental" market track

The Healthy China Action (2019-2030) issued by the Healthy China Action Promotion Committee pointed out that with the development of industrialization, urbanization, population aging and changes in the ecological environment and living behavior, chronic diseases have become the main cause of death and disease burden of residents. The burden caused by chronic diseases such as cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes accounts for more than 70% of the total disease burden, which is an important factor restricting the improvement of healthy life expectancy. Therefore, how to effectively prevent, manage and manage chronic diseases is an important topic related to people's livelihood and health, and it is also urgent to need more scientific and technological intervention.

According to reports, chronic disease management usually refers to the regular examination, continuous monitoring and evaluation of chronic disease risk factors, as well as comprehensive intervention management, treatment effect evaluation and other medical behaviors. The intervention of intelligent home medical equipment is to provide patients with disease risk warning and targeted health improvement programs through the collection of long-term life data, living habits, and changes in conditions at different times, and at the same time provide data support for their visits and follow-up visits, so as to facilitate doctors' accurate treatment.

Zhu Shuyan said that patient chronic disease management is divided into two major scenarios of hospital physical examination and out-of-hospital management, due to the shortage of medical resources, the patient physical examination takes a long time and the experience is poor, the core of home consumption-grade medical instruments is to use advanced technology to miniature and simplify the hospital testing equipment, so that patients can complete routine examinations without admission, reduce the cost of patient testing time and improve the medical experience.

In her view, home medical and health management equipment is a supply-side driven track, and the market size is expected to be in the hundreds of billions. Specifically, the track has potential opportunities to be tapped in the field of stock and increment, "such as the blood glucose meter in the stock field, now most of the blood glucose meters with accurate detection data are invasive detection, can the product be changed to non-invasive detection with the help of advanced technology but the accuracy can meet the requirements to improve the user experience?" For example, products in many fields such as women's health management and spinal sub-health management are incremental markets that need to be further tapped."